Fenretinide and its relation to cancer

Citation
E. Ulukaya et Ej. Wood, Fenretinide and its relation to cancer, CANC TR REV, 25(4), 1999, pp. 229-235
Citations number
74
Categorie Soggetti
Oncology
Journal title
CANCER TREATMENT REVIEWS
ISSN journal
03057372 → ACNP
Volume
25
Issue
4
Year of publication
1999
Pages
229 - 235
Database
ISI
SICI code
0305-7372(199908)25:4<229:FAIRTC>2.0.ZU;2-Z
Abstract
Retinoids, natural or synthetic substances which have vitamin A activity, h ave a well-known reputation for their antitumour and differention-inducing activity in vitro and in vivo. More than 1500 retinoids have been tested so far but very few of them have been entered into clinical trials because of their side-effects. All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenre tinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid. In addition, fenretinide has been shown to induce cell death (apoptosis) even in ATRA-resistant cell lines. Although t he mechanism by which fenretinide acts is not entirely known it is consider ed to be a promising drug and seems to induce apoptosis via different pathw ay(s) from classical retinoids. In this reveiw, we discuss possible mechani sms of fenretinide action and summarize results of clinical trials.